Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia
Executive Summary
The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.
You may also be interested in...
Ardelyx’s Tenapanor Hits Another Regulatory Stumbling Block On Label, Post-Marketing Commitments
While not an outright rejection, the Deficiencies Preclude Discussion letter came as a surprise given the expectation of the drug’s approval for hyperphosphatemia in adults with chronic kidney disease on dialysis.
Keeping Track: Biogen’s Aducanumab Headlines Midsummer Submission Round-Up
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.